Consensus Simulations Plus, Inc. Boerse Muenchen

Stocks

SD3

US8292141053

Advanced Medical Equipment & Technology

Real-time Boerse Muenchen 05:13:27 2026-08-19 EDT			5-day change	1st Jan Change
15.90 ^EUR	0.00%		0.00%	-

07-09	Simulations Plus Fiscal Q3 Adjusted Earnings Decline, Revenue Rises	MT
07-09	Tranche Update on Simulations Plus, Inc.'s Equity Buyback Plan announced on January 4, 2023.	CI

Evolution of the Average Target: Simulations Plus, Inc.

Evolution of the Target Price: Simulations Plus, Inc.

Changes in Analyst Recommendations: Simulations Plus, Inc.

128525b7.ZwiBuJGLgYXDBB3YjENjn-m-qq9UhtTDu1jbbwCqVdU.Kzjq_uW5yfWEQXCxywgop5DsmJ0dyu3z0hfiGkL4G6VXROjxwc7l07dTdg~a9eb7441ec6e1fc2bc05088f833b43a9

Analysts' recommendations: Simulations Plus, Inc.

06-18	Craig-Hallum Downgrades Simulations Plus to Hold From Buy, Adjusts Price Target to $18.50 From $31	MT
06-17	William Blair Downgrades Simulations Plus to Market Perform From Outperform	MT
12-18	BTIG Research Downgrades Simulations Plus to Neutral From Buy	MT
25-09-30	TD Cowen Initiates Simulations Plus at Hold With $16 Price Target	MT
25-07-15	KeyBanc Downgrades Simulations Plus to Sector Weight From Overweight, Removes $25 Price Target	MT
25-07-07	BTIG Adjusts Price Target on Simulations Plus to $25 From $41, Maintains Buy Rating	MT
25-01-08	KeyBanc Lowers Price Target on Simulations Plus to $35 From $40, Keeps Overweight Rating	MT
24-11-15	Stephens Initiates Simulations Plus at Overweight With $39 Price Target	MT
24-07-29	KeyBanc Initiates Simulations Plus at Overweight With $47 Price Target	MT
24-07-16	JMP Securities Initiates Simulations Plus at Market Perform	MT
24-07-03	Top Decliners	MT
24-06-28	William Blair Initiates Simulations Plus at Outperform	MT
24-06-13	Craig-Hallum Raises Price Target on Simulations Plus to $56 From $51, Maintains Buy Rating	MT
24-06-13	Oppenheimer Adjusts Price Target on Simulations Plus to $65 From $55, Maintains Outperform Rating	MT
23-10-26	Oppenheimer Adjusts Simulations Plus Price Target to $55 From $67, Maintains Outperform Rating	MT
23-06-21	Oppenheimer Raises Simulations' Plus Price Target to $67 From $65, Maintains Outperform Rating	MT
23-05-09	BTIG Initiates Simulations Plus at Buy With $55 Price Target	MT
22-12-22	Sidoti Cuts Price Target on Simulations Plus to $44 From $56, Keeps Neutral Rating	MT
22-10-27	Oppenheimer Adjusts Simulations Plus Price Target to $65 From $75, Maintains Outperform Rating	MT
22-08-29	Raymond James Adjusts Price Target on Simulations Plus to $70 From $54, Keeps Outperform Rating	MT
22-08-26	Raymond James Adjusts Simulations Plus Price Target to $70 From $54, Maintains Outperform Rating	MT
22-07-07	Craig Hallum Raises Simulations Plus' Price Target to $60 From $55, Buy Rating Kept	MT
21-10-26	Craig-Hallum Upgrades Simulations Plus to Buy From Hold; Price Target is $53	MT
21-07-13	Simulations Plus : Oppenheimer Adjusts Simulations Plus PT to $75 From $85 Following Fiscal Q3 Miss, Maintains Outperform Rating	MT
21-07-13	Simulations Plus : Craig-Hallum Adjusts Price Target on Simulations Plus to $65 From $74, Maintains Hold Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
VEEVA SYSTEMS INC.			+2.93%
PRO MEDICUS LIMITED			+8.42%
SECTRA AB			+18.96%
HEARTFLOW, INC.			-3.82%
GENERATE BIOMEDICINES, INC.			+59.2%
OMNICELL, INC.			+60.85%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-		+63.47%
ARBUTUS BIOPHARMA CORPORATION	-	-	+13.63%
B-SOFT CO.,LTD.			+70.68%
Average			+32.70%
Weighted average by Cap.			+9.78%